In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

Until recently, available medical immunotherapy regimens yielded a therapeutic response in only 20% of patients. Advances in the understanding of molecular mechanisms of renal cell carcinoma have ...

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...

The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV ...

Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

Some targeted drugs used for the clear cell subtype of renal cell cancer include: Immunotherapy uses your body’s own immune system to fight cancer. These drugs are usually given as an injection ...

Two immunotherapy treatment combinations were ... of exceptional response to immune checkpoint inhibition in renal cell carcinoma, Nature Cancer (2024). 10.1038/s43018-024-00896-w ...

A phase 1 trial of a personalized cancer vaccine for stage III/IV clear cell renal cell carcinoma showed promising results.

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.